Even as the United States and China contest the boundaries of technological exchange, the pharmaceutical sector has emerged as an unlikely zone of continued cooperation. Reports that the U.S. Treasury is drafting rules to preserve American companies' ability to license drugs from Chinese firms sent biopharma stocks surging in Hong Kong, a market signal reflecting something deeper: that healing and commerce, when intertwined, can resist the gravitational pull of geopolitical fracture. The carve-out for weaponizable biotechnology suggests not an open door, but a carefully hinged one — wide enoug